BioMedNewsBreaks

ThursdaySep 24, 2020 11:04 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Partners with Leading Medical Imaging Group for Upcoming Berubicin Clinical Trials

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, has announced that it will partner with Image Analysis Group (“IAG”) for planned Berubicin clinical trials. IAG, a leading medical imaging group, and CNS will work together to provide critical imaging services and imaging data analysis for the trials. IAG has an extensive background of partnering with oncology companies to deliver centralized readings and analysis of patient responses in real time. IAG’s expertise will allow CNS to review efficacy assessments and explore the advanced-treatment manifestations. Because…

Continue Reading

WednesdaySep 23, 2020 9:45 am

BioMedNewsBreaks – Predictive Oncology (NASDAQ: POAI) Granted License for Additional 71 Unique Ovarian Cancer Cell Lines

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has announced that TumorGenesis, a division of the company, has received a license for an additional 71 unique ovarian cancer call lines. The licensing comes from England-based Ximbio, the largest nonprofit in the world dedicated to life science reagents. TumorGenesis now has a total of 96 unique patient-derived ovarian cancer cell lines. Research such as that conducted by TumorGenesis is  the foundation of preclinical research and development. “It is remarkable that the UK cancer researchers using the same media mixes now…

Continue Reading

TuesdaySep 22, 2020 5:03 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP), Sub-Licensee Partner Advancing Lead Drug Candidate in First-Ever Phase 1 and Phase 2 Clinical Trials

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, is advancing its leading drug candidate, Berubicin, to move forward with clinical trials in Poland. This move comes after sub-licensee WPD Pharmaceuticals Inc. has identified a contract research organization — Worldwide Clinical Trials — to coordinate and supervise Phase 1 and Phase 2 trials in the European country (http://ibn.fm/iFYph). A recent article discussing this reads, “Berubicin is proposed for the treatment of glioblastoma multiforme (‘GBM’), an aggressive and incurable form of brain cancer. Berubicin also…

Continue Reading

MondaySep 21, 2020 2:11 pm

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) and HMC HealthWorks Enter Sales and Distribution Partnership

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital-therapeutics market, together with HMC HealthWorks, a 40-year veteran in health-care management with clinically-integrated models of care that reduce health-care costs and improve population health, today announced entry into a sales and distribution agreement. Under the partnership, HMC will incorporate DarioHealth's digital therapeutics solution into its care management programs on a stand-alone basis as well as for incorporation within HMC’s comprehensive solutions. "We believe that this agreement with HMC is further validation of the progress we have made in transitioning to a leading provider of digital-therapeutics solutions to payors, employers and other…

Continue Reading

MondaySep 21, 2020 1:24 pm

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Appoints Seasoned Biotech Executive to Advance Expanding IP Estate

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced it has named Thomas C. Gallagher, Esq. as its senior vice president of Intellectual Property and Licensing. According to the update, Gallagher has extensive experience in the area of biotechnology intellectual property (“IP”) law, business development and licensing transactions with industry and academic institutions. “Mr. Gallagher will play a critical role in advancing our expanding intellectual property estate by spearheading IP strategy, which is an important element of the company’s overall success and value creation,” said Genprex president and CEO…

Continue Reading

MondaySep 21, 2020 11:10 am

BioMedNewsBreaks – LexaGene Holdings, Inc. (TSX.V: LXG) (OTCQB: LXXGF) Announces Engagement of Tailwinds Research Group, Video Update and Strategic Advisory Board Appointment

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, on Friday announced its engagement of Tailwinds Research Group to provide digital content distribution for the company. According to the update, the engagement will cover a 1-year term, at US$2,500/month with 100,000 stock options provided at C$0.88/option. In addition, LexaGene today released a video message from its founder and CEO, Dr. Jack Regan, that highlighted the company’s progress toward commercial sales and announced the appointment of Dr. Shelley Rankin to LexaGene’s Scientific Advisory Board. “As we approach sales, I’m very pleased to…

Continue Reading

FridaySep 18, 2020 1:12 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI), Helomics Provide Key Insight to Personalized Cancer Treatment

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine, lives by the motto: Cancer is personal; we believe therapy should be too. The company’s subsidiary Helomics builds AI-driven models designed to predict drug response and patient outcome of individual tumors. The company is able to do that because it relies on POAI’s tumor inventory, one of the largest in the world. POAI is a leader in working with oncologists in offering a functional precision medicine approach to treating cancer. Key information provided by Predictive Oncology can improve a patient’s odds in the fight against…

Continue Reading

FridaySep 18, 2020 12:25 pm

BioMedNewsBreaks – IDEAYA Biosciences Inc. (NASDAQ: IDYA) Announces ‘Transformational’ Second Quarter

IDEAYA Biosciences (NASDAQ: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, recently provided a business update and announced financial results for the second quarter ended June 30, 2020. "This quarter was transformational for IDEAYA. We have cash runway into 2024, with quarter-end cash, cash equivalents and marketable securities of $172.0 million supplemented by $127.5 million aggregate gross proceeds received subsequently, including $100 million non-dilutive upfront cash and $20 million private placement equity investment from GSK,” said Yujiro S. Hata, CEO and president of IDEAYA Biosciences, in the press release. “In addition, through our…

Continue Reading

ThursdaySep 17, 2020 10:13 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Slated to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, announced it will be one of the companies appearing at this year’s online  Oppenheimer Fall Healthcare Life Sciences & MedTech Summit; the event is scheduled for Tuesday, Sept. 2020. The company’s CEO John Climaco will make the virtual presentation as well as hold one-on-one virtual investor meetings throughout the event. The summit will begin at 10 a.m. EDT, and a replay of Climaco’s presentation will be available on the company's website for 90 days after the…

Continue Reading

WednesdaySep 16, 2020 2:38 pm

BioMedNewsBreaks – Revive Therapeutics Ltd. (CSE: RV) (OTC: RVVTF) Receives IRB Approval for Bucilliamine COVID-19 Treatment Program

Revive Therapeutics (CSE: RVV) (OTC: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced that is has received approval from the independent Institutional Review Board ("IRB") for one of its programs. The program is Revive’s expanded access protocol (“EAP”) for compassionate use of Bucillamine in the treatment of COVID-19. The EAP comprises a multi-center, open-label study of Bucillamine in hospitalized patients suffering from severe COVID-19. The study calls for patients to receive Bucillamine 200 mg orally, three times a day for up to 14 days. Patients will be…

Continue Reading